scholarly journals Influence of Renin-Angiotensin System Inhibitors on Lower Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
Timothy M E Davis ◽  
Wendy A Davis
Keyword(s):  
Type 2 Diabetes ◽  
Respiratory Tract ◽  
Phase Ii ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Study Phase ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections

Objective:<b> </b>To determine whether<b> </b>angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower respiratory tract infections complicating type 2 diabetes. <p>Research design and methods:<b> </b>Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age of 65.8 years, 51.6% were males, median diabetes duration 9.0 years). All were followed for hospitalizations for/with, or deaths from, pneumonia/influenza ascertained from validated administrative data linkage from study entry to end-2016. Cox and competing risk regression were used to identify independent predictors of this outcome.</p> <p>Results:<b> </b>Two-thirds of participants (n=982) were taking an ACEi and/or ARB at study entry (498 (33.6%) ACEi, 408 (27.5%) ARB, 76 (5.1%) both).<b> </b>During 9,511 person-years of follow-up (mean 6.4±2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations, 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio (HR) (95% confidence interval) 0.64 (0.45, 0.89), <i>P</i>=0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 (0.48, 0.95), <i>P</i>=0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up (interaction with ln(time), <i>P</i>=0.70). Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables.</p> <p>Conclusions:<b> </b>ACEi/ARB reduce the risk of pneumonia/influenza in community-based people with type 2 diabetes.<b><br> </b></p>

scholarly journals Influence of Renin-Angiotensin System Inhibitors on Lower Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
Timothy M E Davis ◽  
Wendy A Davis
Keyword(s):  
Type 2 Diabetes ◽  
Respiratory Tract ◽  
Phase Ii ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Study Phase ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections

Objective:<b> </b>To determine whether<b> </b>angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower respiratory tract infections complicating type 2 diabetes. <p>Research design and methods:<b> </b>Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age of 65.8 years, 51.6% were males, median diabetes duration 9.0 years). All were followed for hospitalizations for/with, or deaths from, pneumonia/influenza ascertained from validated administrative data linkage from study entry to end-2016. Cox and competing risk regression were used to identify independent predictors of this outcome.</p> <p>Results:<b> </b>Two-thirds of participants (n=982) were taking an ACEi and/or ARB at study entry (498 (33.6%) ACEi, 408 (27.5%) ARB, 76 (5.1%) both).<b> </b>During 9,511 person-years of follow-up (mean 6.4±2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations, 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio (HR) (95% confidence interval) 0.64 (0.45, 0.89), <i>P</i>=0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 (0.48, 0.95), <i>P</i>=0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up (interaction with ln(time), <i>P</i>=0.70). Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables.</p> <p>Conclusions:<b> </b>ACEi/ARB reduce the risk of pneumonia/influenza in community-based people with type 2 diabetes.<b><br> </b></p>

Interferon signature in immunosuppressed patients with lower respiratory tract infections: dosage on bronchoalveolar lavage

2020 ◽  
Vol 111 (3) ◽  
Author(s):  
Massimiliano Bergallo ◽  
Linda Ferrari ◽  
Giulia Faolotto ◽  
Piero E. Balbo ◽  
Paola Montanari ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Bronchoalveolar Lavage ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Lower Respiratory Tract Infections ◽  
Interferon Signature ◽  
Immunosuppressed Patients ◽  
Tract Infections
Sign in / Sign up

Export Citation Format

Share Document